Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Abstract Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6–10 months. We conducted a phase II trial of upfront 5‐day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblastoma. Patients received up to four...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Emil Lou, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon II, April Coan, Leighann Bailey, Scott Turner, Henry S. Friedman, James J. Vredenburgh
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2013-04-01
coleção:	Cancer Medicine
Assuntos:	Bevacizumab glioblastoma neoadjuvant therapy temozolomide unresectable upfront
Acesso em linha:	https://doi.org/10.1002/cam4.58
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!